A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma

Trial Profile

A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Bavituximab (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Oct 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrials.gov.
    • 10 May 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top